{"id":62918,"date":"2026-04-12T22:21:21","date_gmt":"2026-04-12T14:21:21","guid":{"rendered":"https:\/\/flcube.com\/?p=62918"},"modified":"2026-04-12T22:21:22","modified_gmt":"2026-04-12T14:21:22","slug":"sino-biopharm-doses-first-patient-in-phase-ii-study-of-kylo-11-first-in-class-sirna-targeting-lpa-for-cardiovascular-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62918","title":{"rendered":"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease"},"content":{"rendered":"\n<p><strong>Sino Biopharmaceutical Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG:\u202f1177<\/a>) announced <strong>first patient enrollment<\/strong> in the <strong>Phase II Kylo-11-II-C01 study<\/strong> evaluating <strong>Kylo-11<\/strong>, a <strong>novel siRNA drug targeting lipoprotein(a) [Lp(a)]<\/strong>, in patients with <strong>atherosclerotic cardiovascular disease (ASCVD)<\/strong> and <strong>elevated Lp(a)<\/strong> levels.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>Kylo-11-II-C01<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Phase II<\/td><\/tr><tr><td><strong>First Patient<\/strong><\/td><td>Enrolled April\u202f2026<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Kylo-11 (siRNA therapeutic)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td><strong>LPA<\/strong> (lipoprotein(a))<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>ASCVD with elevated Lp(a)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-differentiation\">Technology Platform &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> <strong>MVIP Delivery Platform<\/strong> \u2013 <strong>China&#8217;s first globally patented siRNA delivery technology<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>World&#8217;s first dual-conjugated siRNA delivery technology<\/strong><\/li>\n\n\n\n<li><strong>Key Features:<\/strong><\/li>\n\n\n\n<li><strong>Efficient cellular delivery<\/strong> enhancing tissue penetration<\/li>\n\n\n\n<li><strong>Protection of antisense strand<\/strong> from exonuclease degradation<\/li>\n\n\n\n<li><strong>Enhanced in vivo stability<\/strong> prolonging therapeutic activity<\/li>\n\n\n\n<li><strong>Reduced plasma degradation<\/strong> of antisense strand improving bioavailability<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> <strong>Ultra-long-lasting effects<\/strong> enabling extended dosing intervals vs. conventional siRNA therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action\">Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>LPA gene<\/strong> \u2013 encodes apolipoprotein(a), a causal risk factor for ASCVD independent of LDL cholesterol<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> siRNA-mediated <strong>gene silencing<\/strong> reduces hepatic Lp(a) production<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> <strong>~20% of global population<\/strong> has elevated Lp(a); no approved targeted therapies currently available<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lp(a) Inhibitor Market:<\/strong> Projected <strong>US$10\u201115\u202fbillion<\/strong> peak opportunity; validated by Novartis pelacarsen and Amgen olpasiran Phase\u202fII data<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong><\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Asset<\/th><th>Mechanism<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td>Novartis<\/td><td>Pelacarsen<\/td><td>ASO (antisense oligonucleotide)<\/td><td>Phase\u202fIII (HORIZON)<\/td><\/tr><tr><td>Amgen<\/td><td>Olpasiran<\/td><td>siRNA<\/td><td>Phase\u202fII<\/td><\/tr><tr><td><strong>Sino Biopharm<\/strong><\/td><td><strong>Kylo-11<\/strong><\/td><td><strong>siRNA (MVIP platform)<\/strong><\/td><td><strong>Phase\u202fII (initiated)<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiation:<\/strong> MVIP platform&#8217;s <strong>dual-conjugation technology<\/strong> may offer <strong>superior durability and potency<\/strong> vs. first-generation siRNA delivery systems<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> First-mover position in <strong>China siRNA cardiovascular space<\/strong>; platform applicable to <strong>hepatic-targeted gene silencing<\/strong> across metabolic and rare diseases<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Peak China sales estimated at <strong>RMB 2\u20113\u202fbillion<\/strong> (US$280\u2011420\u202fmillion) by 2033 assuming 2029\u20112030 launch and 15\u201120% penetration in eligible ASCVD population<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial outcomes, platform validation, and commercial projections for Kylo-11. Actual results may differ due to risks including efficacy failures, safety signals, competitive advances from Novartis\/Amgen programs, and regulatory requirements for novel siRNA delivery technologies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041000002_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026041000002_c.\"><\/object><a id=\"wp-block-file--media-4d7baf63-2aa2-4de7-900b-5361478fc68f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041000002_c.pdf\">2026041000002_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041000002_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4d7baf63-2aa2-4de7-900b-5361478fc68f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,69,908,64,313],"class_list":["post-62918","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cvd","tag-hkg-1177","tag-rnai-aso","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating Kylo-11, a novel siRNA drug targeting lipoprotein(a) [Lp(a)], in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) levels.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62918\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating Kylo-11, a novel siRNA drug targeting lipoprotein(a) [Lp(a)], in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) levels.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62918\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-12T14:21:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-12T14:21:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62918#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62918\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease\",\"datePublished\":\"2026-04-12T14:21:21+00:00\",\"dateModified\":\"2026-04-12T14:21:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62918\"},\"wordCount\":353,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CVD\",\"HKG: 1177\",\"RNAi \\\/ ASO\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62918#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62918\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62918\",\"name\":\"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-12T14:21:21+00:00\",\"dateModified\":\"2026-04-12T14:21:22+00:00\",\"description\":\"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating Kylo-11, a novel siRNA drug targeting lipoprotein(a) [Lp(a)], in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) levels.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62918#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62918\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62918#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating Kylo-11, a novel siRNA drug targeting lipoprotein(a) [Lp(a)], in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) levels.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62918","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease","og_description":"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating Kylo-11, a novel siRNA drug targeting lipoprotein(a) [Lp(a)], in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) levels.","og_url":"https:\/\/flcube.com\/?p=62918","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-12T14:21:21+00:00","article_modified_time":"2026-04-12T14:21:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62918#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62918"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease","datePublished":"2026-04-12T14:21:21+00:00","dateModified":"2026-04-12T14:21:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62918"},"wordCount":353,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CVD","HKG: 1177","RNAi \/ ASO","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62918#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62918","url":"https:\/\/flcube.com\/?p=62918","name":"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-12T14:21:21+00:00","dateModified":"2026-04-12T14:21:22+00:00","description":"Sino Biopharmaceutical Ltd (HKG:\u202f1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating Kylo-11, a novel siRNA drug targeting lipoprotein(a) [Lp(a)], in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) levels.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62918#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62918"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62918#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 \u2013 First-in-Class siRNA Targeting LPA for Cardiovascular Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62918"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62918\/revisions"}],"predecessor-version":[{"id":62940,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62918\/revisions\/62940"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}